Exam Points
- The FDA approved vepdegestrant on 1 May 2026.
- Brand name: Veppanu.
- It is indicated for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy.
- It is the first FDA-approved PROTAC-based targeted protein degrader.
- PROTAC stands for Proteolysis-Targeting Chimera.
- PROTACs remove target proteins by using the cell’s ubiquitin-proteasome system.
- Vepdegestrant targets and degrades the estrogen receptor.
- ESR1 mutations can cause resistance to endocrine therapy in breast cancer.
- The FDA approval was based on the Phase 3 VERITAC-2 trial.
- In the ESR1-mutated subgroup, vepdegestrant showed median progression-free survival of about 5.0 months compared with 2.1 months for fulvestrant.
- Vepdegestrant is an oral therapy, while fulvestrant is given by injection.
- FDA also approved Guardant360 CDx as a companion diagnostic to identify ESR1 mutations.
News Item
The U.S. Food and Drug Administration (FDA) approved vepdegestrant, sold as Veppanu, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy. The approval is significant because vepdegestrant is the first FDA-approved PROTAC-based targeted protein degrader, a therapy designed to remove disease-causing proteins rather than only block them.
Background
Traditional medicines often work by blocking the activity of a disease-related protein. However, many proteins are difficult to block and are called “undruggable”. PROTACs offer a different approach: they act like a molecular bridge, bringing the target protein close to the cell’s own protein-disposal machinery so that it is tagged and degraded. Vepdegestrant targets the estrogen receptor, which can drive growth in many breast cancers, especially when ESR1 mutations make tumours resistant to standard endocrine therapies.
Prelims Facts
- The FDA approved vepdegestrant on 1 May 2026.
- Brand name: Veppanu.
- It is indicated for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy.
- It is the first FDA-approved PROTAC-based targeted protein degrader.
- PROTAC stands for Proteolysis-Targeting Chimera.
- PROTACs remove target proteins by using the cell’s ubiquitin-proteasome system.
- Vepdegestrant targets and degrades the estrogen receptor.
- ESR1 mutations can cause resistance to endocrine therapy in breast cancer.
- The FDA approval was based on the Phase 3 VERITAC-2 trial.
- In the ESR1-mutated subgroup, vepdegestrant showed median progression-free survival of about 5.0 months compared with 2.1 months for fulvestrant.
- Vepdegestrant is an oral therapy, while fulvestrant is given by injection.
- FDA also approved Guardant360 CDx as a companion diagnostic to identify ESR1 mutations.
Mains Focus & Analysis
- Vepdegestrant’s approval is a landmark in biotechnology because it validates targeted protein degradation as a clinical drug platform. It may open a new class of medicines against proteins earlier considered difficult to drug. However, the field still faces challenges: PROTAC molecules are often large, tissue delivery can be difficult, only some E3 ligases are well understood, and cancers may develop resistance. Therefore, the approval is both a major scientific breakthrough and the beginning of a longer phase of clinical refinement.
GS Mapping
GS3: Biotechnology, Health Technology, Cancer Therapy, Scientific Innovation; GS2: Health Governance and Regulation
Quick Check · 1 question
Explanation: All three statements are correct. Vepdegestrant is a PROTAC-based targeted protein degrader approved for eligible ESR1-mutated ER-positive, HER2-negative advanced or metastatic breast cancer, and PROTACs work by promoting degradation of specific target proteins.
परीक्षा बिंदु (Exam Points)
- FDA ने vepdegestrant को 1 May 2026 को approve किया।
- Brand name: Veppanu.
- यह ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer वाले adults के लिए है, जिनकी disease endocrine therapy के बाद progress हो चुकी है।
- यह पहला FDA-approved PROTAC-based targeted protein degrader है।
- PROTAC का पूरा नाम Proteolysis-Targeting Chimera है।
- PROTACs cell के ubiquitin-proteasome system का उपयोग करके target proteins को remove करते हैं।
- Vepdegestrant estrogen receptor को target और degrade करता है।
- ESR1 mutations breast cancer में endocrine therapy resistance पैदा कर सकते हैं।
- FDA approval Phase 3 VERITAC-2 trial पर आधारित था।
- ESR1-mutated subgroup में vepdegestrant ने लगभग 5.0 months median progression-free survival दिखाया, जबकि fulvestrant में यह 2.1 months था।
- Vepdegestrant एक oral therapy है, जबकि fulvestrant injection से दी जाती है।
- FDA ने ESR1 mutations की पहचान के लिए Guardant360 CDx companion diagnostic को भी approve किया।
समाचार
U.S. Food and Drug Administration (FDA) ने vepdegestrant, जिसे Veppanu नाम से बेचा जाएगा, को ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer वाले adults के लिए मंजूरी दी, जिनकी disease endocrine therapy के बाद आगे बढ़ चुकी है। यह approval महत्वपूर्ण है क्योंकि vepdegestrant पहला FDA-approved PROTAC-based targeted protein degrader है, जो disease-causing proteins को केवल block करने के बजाय cell से remove करने के लिए design किया गया है।
पृष्ठभूमि
पारंपरिक दवाएं अक्सर किसी disease-related protein की activity को block करके काम करती हैं। लेकिन कई proteins को block करना कठिन होता है, इसलिए उन्हें “undruggable” कहा जाता है। PROTACs अलग approach अपनाते हैं: वे molecular bridge की तरह target protein को cell की protein-disposal machinery के पास लाते हैं, जिससे वह tag होकर degrade हो जाता है। Vepdegestrant estrogen receptor को target करता है, जो कई breast cancers की growth को drive कर सकता है, खासकर जब ESR1 mutations tumours को standard endocrine therapies के प्रति resistant बना देते हैं।
प्रारंभिक परीक्षा तथ्य
- FDA ने vepdegestrant को 1 May 2026 को approve किया।
- Brand name: Veppanu.
- यह ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer वाले adults के लिए है, जिनकी disease endocrine therapy के बाद progress हो चुकी है।
- यह पहला FDA-approved PROTAC-based targeted protein degrader है।
- PROTAC का पूरा नाम Proteolysis-Targeting Chimera है।
- PROTACs cell के ubiquitin-proteasome system का उपयोग करके target proteins को remove करते हैं।
- Vepdegestrant estrogen receptor को target और degrade करता है।
- ESR1 mutations breast cancer में endocrine therapy resistance पैदा कर सकते हैं।
- FDA approval Phase 3 VERITAC-2 trial पर आधारित था।
- ESR1-mutated subgroup में vepdegestrant ने लगभग 5.0 months median progression-free survival दिखाया, जबकि fulvestrant में यह 2.1 months था।
- Vepdegestrant एक oral therapy है, जबकि fulvestrant injection से दी जाती है।
- FDA ने ESR1 mutations की पहचान के लिए Guardant360 CDx companion diagnostic को भी approve किया।
मुख्य परीक्षा दृष्टिकोण (विश्लेषण)
- Vepdegestrant का approval biotechnology में landmark है क्योंकि यह targeted protein degradation को clinical drug platform के रूप में validate करता है। इससे उन proteins के खिलाफ medicines की नई class विकसित हो सकती है जिन्हें पहले target करना कठिन माना जाता था। फिर भी field में challenges हैं: PROTAC molecules अक्सर बड़े होते हैं, tissue delivery कठिन हो सकती है, केवल कुछ E3 ligases अच्छी तरह समझे गए हैं और cancers resistance develop कर सकते हैं। इसलिए यह approval बड़ा scientific breakthrough भी है और clinical refinement के लंबे phase की शुरुआत भी।
जीएस मैपिंग
GS3: biotechnology, health technology, cancer therapy, scientific innovation; GS2: health governance और regulation
त्वरित अभ्यास · 1 प्रश्न
व्याख्या: तीनों कथन सही हैं। Vepdegestrant eligible ESR1-mutated ER-positive, HER2-negative advanced or metastatic breast cancer के लिए approved PROTAC-based targeted protein degrader है और PROTACs specific target proteins के degradation को promote करते हैं।
